title: Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
authors.affiliation: Department of Endocrine Oncology,  University Hospital,  Uppsala University, Uppsala,  Sweden.
authors.forename: K
authors.initials: K
authors.lastname: Öberg
authors.forename: U
authors.initials: U
authors.lastname: Knigge
authors.forename: D
authors.initials: D
authors.lastname: Kwekkeboom
authors.forename: A
authors.initials: A
authors.lastname: Perren
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D007414:Intestinal Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal